| 5.68 0.08 (1.43%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.95 |
1-year : | 8.12 |
| Resists | First : | 5.95 |
Second : | 6.95 |
| Pivot price | 5.61 |
|||
| Supports | First : | 5.52 |
Second : | 5.26 |
| MAs | MA(5) : | 5.54 |
MA(20) : | 5.59 |
| MA(100) : | 5.31  |
MA(250) : | 7.11 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.8 |
D(3) : | 40.7 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 12.38 | Low : | 4.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AUPH ] has closed below upper band by 38.0%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.7 - 5.72 | 5.72 - 5.74 |
| Low: | 5.53 - 5.56 | 5.56 - 5.58 |
| Close: | 5.64 - 5.68 | 5.68 - 5.71 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Thu, 25 Jul 2024
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat
Thu, 25 Jul 2024
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - Defense World
Wed, 24 Jul 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 4.4% Higher - MarketBeat
Sun, 21 Jul 2024
Oppenheimer & Co. Inc. Sells 3,700 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Sat, 20 Jul 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Below 200-Day Moving Average of $5.99 - American Banking and Market News
Fri, 19 Jul 2024
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 143 (M) |
| Shares Float | 127 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 40.2 (%) |
| Shares Short | 10,320 (K) |
| Shares Short P.Month | 9,210 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.5 |
| Profit Margin | -32.7 % |
| Operating Margin | -13.1 % |
| Return on Assets (ttm) | -8.2 % |
| Return on Equity (ttm) | -16.7 % |
| Qtrly Rev. Growth | 46.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.33 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | -13.21 |
| PEG Ratio | 0 |
| Price to Book value | 2.27 |
| Price to Sales | 4.24 |
| Price to Cash Flow | -39.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|